| Organism | Drug Class | Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| Plasmodium spp | Antimalarial Aminoquinoline | Sanofi | Ferroquine | SR-97193 | Phase II | Terminated |
|
| Plasmodium spp | Antimalarial Endoperoxides | GlaxoSmithKline | Tafenoquine; Etaquine | WR 238605; SB-252263 | Phase II/III | Recruiting |
006901
|
| Plasmodium spp | Antimalarial Spiroindolone | Novartis | KAE-609 | NITD-609 | Phase II | Recruiting |
|
| Plasmodium spp | Antimalarial Trioxolane | Medicines for Malaria Venture | OZ-439 | MMV-08/1019 | Phase II | Not Yet Recruiting |
|
| Plasmodium spp | Combination | Policlinique Medicale Universitaire | Cotrifazid | Rifampicin and Cotrimoxazole and Isoniazid | Phase II | Terminated |
|
| Plasmodium spp | Combination | Pfizer | Azithromycin and Chloroquine | AZCQ; Zithromax and Chloroquine; Zmax and Chloroquine | Phase III | Recruiting |
|
| Plasmodium spp | Combination | Holley Pharm; Holleykin Pharm | Eurartesim; Artekin™; Duocotecxin™ | Dihydroartemisinin and Piperaquine | Phase III | Completed |
|
| Plasmodium spp | Combination | Jomaa Pharma | Fosclin; JP-01 | Clindamycin and Fosmidomycin | Phase III | Completed |
|
| Plasmodium spp | DNA Synthesis Inhibitor | Pfizer; Mission Pharmacal | Tindamax™; Fasigyn™; Simplotan™ | Tinidazole | Phase II | Unknown |
007940
|
| Plasmodium spp | Electron Transport Chain Inhibitor | GlaxoSmithKline | GSK932121 | | Phase I | Terminated (Toxicity) |
|
| Plasmodium spp | Hemozoin Inhibitor | Tulane University Health Center | AQ-13 | Aminoquinoline | Phase II | Not Yet Recruiting |
|
| Plasmodium spp | Inhibition of Phospholipid Metabolism | Sanofi-Aventis | SAR97276A | 1,12-Bis[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium]dodecane dibromide | Phase II | Terminated |
|
| Toxoplasma gondii | Protein Synthesis Inhibitor (binds to 50S subunit) | Rhone-Poulenc Pharmaceuticals | Rovamycine™ | Spiramycin | Phase III | Recruiting |
007350
|